Abstract

The majority of epilepsies are focal in origin, with seizures emanating from one brain region. Although focal epilepsies often arise from structural brain lesions, many affected individuals have normal brain imaging. The etiology is unknown in the majority of individuals, although genetic factors are increasingly recognized. Autosomal dominant familial focal epilepsy with variable foci (FFEVF) is notable because family members have seizures originating from different cortical regions1. Using exome sequencing, we detected DEPDC5 mutations in two affected families. We subsequently identified mutations in five of six additional published large families with FFEVF. Study of families with focal epilepsy that were too small for conventional clinical diagnosis with FFEVF identified DEPDC5 mutations in approximately 12% of families (10/82). This high frequency establishes DEPDC5 mutations as a common cause of familial focal epilepsies. Shared homology with G protein signaling molecules and localization in human neurons suggest a role of DEPDC5 in neuronal signal transduction.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

NCBI Reference Sequence

References

  1. 1.

    et al. Familial partial epilepsy with variable foci: a new partial epilepsy syndrome with suggestion of linkage to chromosome 2. Ann. Neurol. 44, 890–899 (1998).

  2. 2.

    et al. Mapping of a gene determining familial partial epilepsy with variable foci to chromosome 22q11-q12. Am. J. Hum. Genet. 65, 1698–1710 (1999).

  3. 3.

    et al. Familial partial epilepsy with variable foci in a Dutch family: clinical characteristics and confirmation of linkage to chromosome 22q. Epilepsia 44, 1298–1305 (2003).

  4. 4.

    et al. Familial partial epilepsy with variable foci: clinical features and linkage to chromosome 22q12. Epilepsia 45, 1054–1060 (2004).

  5. 5.

    et al. Familial focal epilepsy with variable foci mapped to chromosome 22q12: expansion of the phenotypic spectrum. Epilepsia 53, e151–e155 (2012).

  6. 6.

    et al. Familial partial epilepsy with variable foci: a new family with suggestion of linkage to chromosome 22q12. Epilepsia 51, 1910–1914 (2010).

  7. 7.

    et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources. Am. J. Hum. Genet. 84, 524–533 (2009).

  8. 8.

    , , , & Channelopathies in idiopathic epilepsy. Neurotherapeutics 4, 295–304 (2007).

  9. 9.

    et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturanl frontal lobe epilepsy. Nat. Genet. 44, 1188–1190 (2012).

  10. 10.

    & Genetic variations and associated pathophysiology in the management of epilepsy. Appl. Clin. Genet. 4, 113–125 (2011).

  11. 11.

    & DEP domains: more than just membrane anchors. Dev. Cell 11, 436–438 (2006).

  12. 12.

    et al. Electrochemical cues regulate assembly of the Frizzled/Dishevelled complex at the plasma membrane during planar epithelial polarization. Nat. Cell Biol. 11, 286–294 (2009).

  13. 13.

    et al. Conformational stability studies of the pleckstrin DEP domain: definition of the domain boundaries. Biochim. Biophys. Acta 1385, 157–164 (1998).

  14. 14.

    et al. Characterization of function of three domains in dishevelled-1: DEP domain is responsible for membrane translocation of dishevelled-1. Cell Res. 14, 324–330 (2004).

  15. 15.

    & WNTs in synapse formation and neuronal circuitry. EMBO J. 31, 2697–2704 (2012).

  16. 16.

    et al. Partial epilepsy with pericentral spikes: a new familial epilepsy syndrome with evidence for linkage to chromosome 4p15. Ann. Neurol. 51, 740–749 (2002).

  17. 17.

    & Generalized epilepsy with febrile seizures plus: a genetic disorder with heterogenous clinical phenotypes. Brain 120, 479–490 (1997).

  18. 18.

    et al. A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures. Nat. Genet. 40, 322–328 (2008).

  19. 19.

    et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat. Genet. 41, 160–162 (2009).

  20. 20.

    et al. Familial mesial temporal lobe epilepsy: a benign epilepsy syndrome showing complex inheritance. Brain 133, 3221–3231 (2010).

  21. 21.

    , , & Validation of a questionnaire for clinical seizure diagnosis. Epilepsia 33, 1065–1071 (1992).

  22. 22.

    & Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).

  23. 23.

    , , , & Housekeeping and tissue-specific genes in mouse tissues. BMC Genomics 8, 127 (2007).

  24. 24.

    et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917–1920 (2007).

  25. 25.

    & Neural differentiation of human embryonic stem cells. Methods Mol. Biol. 438, 19–30 (2008).

  26. 26.

    , , , & Synergy between all-trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells. Blood 102, 237–245 (2003).

Download references

Acknowledgements

We thank the individuals with epilepsy and their families for participating in our research. We thank B. Johns and R. Schultz for technical assistance and M. Broli, F. Provini, S. Foote and K. Praveen for assistance with family studies. We thank the Leiden Genome Technology Centre (LGTC) for exome sequencing of family D1. This work was supported by the National Health and Medical Research Council of Australia (Program grant 628952 to S.F.B., I.E.S., L.M.D., P.Q.T. and J.G., Australia Fellowship 466671 to S.F.B., Senior Research Fellowship 508043 to J.G., Practitioner Fellowship 1006110 to I.E.S., Training Fellowship 1016715 to S.E.H. and Career Development Fellowship 1032603 to L.M.D.) and by the Center of Medical System Biology (CMSB) established by the Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research (NGI/NWO) to A.M.J.M.v.d.M., the Netherlands Organization for Scientific Research (NWO, 940-33-030) and the Dutch National Epilepsy Fund (98-14). P.M.C.C. received an unrestricted research grant from UCB Pharma (The Netherlands). J.S. received financial support from the Spanish government (grants EUI-EURC-2011-4325 within the EuroEPINOMICS-RES network and grant SAF2010-18586). D.E.C. received an unrestricted educational grant from UCB Pharma. P.Q.T. is a Pfizer Australia Research Fellow. K.M.K. was supported by a research fellowship from the Deutsche Forschungsgemeinschaft (KL 2254/1-1) and a scholarship from The University of Melbourne. This study makes use of data generated by the DECIPHER Consortium. A full list of centers who contributed to the generation of the data is available from the consortium website and via e-mail (decipher@sanger.ac.uk). Funding for the project was provided by the Wellcome Trust.

Author information

Author notes

    • Leanne M Dibbens
    •  & Boukje de Vries

    These authors contributed equally to this work.

Affiliations

  1. Epilepsy Research Program, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.

    • Leanne M Dibbens
    • , Sarah E Heron
    • , Bree L Hodgson
    •  & Xenia Iona
  2. Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia.

    • Leanne M Dibbens
    •  & Sarah E Heron
  3. Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands.

    • Boukje de Vries
    • , Claudia M Weller
    •  & Arn M J M van den Maagdenberg
  4. Laboratory of Experimental Neurology, Université Libre de Bruxelles, Brussels, Belgium.

    • Simona Donatello
    • , Satyan Chintawar
    •  & Massimo Pandolfo
  5. Northern Health, Melbourne, Victoria, Australia.

    • Douglas E Crompton
  6. Epilepsy Research Centre, Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.

    • Douglas E Crompton
    • , Susannah T Bellows
    • , Karl Martin Klein
    • , Brigid M Regan
    • , Samuel F Berkovic
    •  & Ingrid E Scheffer
  7. School of Molecular and Biomedical Science, The University of Adelaide, Adelaide, South Australia, Australia.

    • James N Hughes
    • , John C Mulley
    • , Paul Q Thomas
    •  & Jozef Gecz
  8. Epilepsy Center Hessen, Department of Neurology, University Hospitals Giessen & Marburg, Campus Marburg, Philipps-University Marburg, Marburg, Germany.

    • Karl Martin Klein
  9. Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

    • Petra M C Callenbach
    •  & Oebele F Brouwer
  10. Neurogenetics Program, SA Pathology at Women's and Children's Hospital, Adelaide, South Australia, Australia.

    • Mark A Corbett
    •  & Alison E Gardner
  11. Schneider Children's Medical Center of Israel, Petach Tikvah, Israel.

    • Sara Kivity
  12. Central Coast Area Health Authority, Gosford, New South Wales, Australia.

    • Denis Crimmins
  13. Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.

    • Terence J O'Brien
  14. Epilepsy Unit, Hospital Universitario Fundación Jiménez Diaz and Centro De Investigación Biomédica En Red De Enfermedades Raras (CIBERER), Madrid, Spain.

    • Rosa Guerrero-López
    •  & Jose Serratosa
  15. Genetic Medicine, SA Pathology at Women's and Children's Hospital, Adelaide, South Australia, Australia.

    • John C Mulley
  16. School of Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, South Australia, Australia.

    • John C Mulley
    •  & Jozef Gecz
  17. Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.

    • Francois Dubeau
    • , Frederick Andermann
    •  & Eva Andermann
  18. IRCCS (Instituto di Ricovero e Cura a Carattere Scientifico), Istituto di Scienze Neurologiche, University of Bologna, Bologna, Italy.

    • Laura Licchetta
    •  & Francesca Bisulli
  19. CHUM (Centre Hospitalier de l'Université de Montréal) Research Center, University of Montreal, Montreal, Quebec, Canada.

    • Patrick Cossette
  20. Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.

    • Arn M J M van den Maagdenberg
  21. Florey Neuroscience Institute, Melbourne, Victoria, Australia.

    • Ingrid E Scheffer
  22. Department of Paediatrics, The University of Melbourne, Royal Children's Hospital, Melbourne, Victoria, Australia.

    • Ingrid E Scheffer

Authors

  1. Search for Leanne M Dibbens in:

  2. Search for Boukje de Vries in:

  3. Search for Simona Donatello in:

  4. Search for Sarah E Heron in:

  5. Search for Bree L Hodgson in:

  6. Search for Satyan Chintawar in:

  7. Search for Douglas E Crompton in:

  8. Search for James N Hughes in:

  9. Search for Susannah T Bellows in:

  10. Search for Karl Martin Klein in:

  11. Search for Petra M C Callenbach in:

  12. Search for Mark A Corbett in:

  13. Search for Alison E Gardner in:

  14. Search for Sara Kivity in:

  15. Search for Xenia Iona in:

  16. Search for Brigid M Regan in:

  17. Search for Claudia M Weller in:

  18. Search for Denis Crimmins in:

  19. Search for Terence J O'Brien in:

  20. Search for Rosa Guerrero-López in:

  21. Search for John C Mulley in:

  22. Search for Francois Dubeau in:

  23. Search for Laura Licchetta in:

  24. Search for Francesca Bisulli in:

  25. Search for Patrick Cossette in:

  26. Search for Paul Q Thomas in:

  27. Search for Jozef Gecz in:

  28. Search for Jose Serratosa in:

  29. Search for Oebele F Brouwer in:

  30. Search for Frederick Andermann in:

  31. Search for Eva Andermann in:

  32. Search for Arn M J M van den Maagdenberg in:

  33. Search for Massimo Pandolfo in:

  34. Search for Samuel F Berkovic in:

  35. Search for Ingrid E Scheffer in:

Contributions

L.M.D. designed and oversaw the molecular genetic aspects of the study, coordinated the study and wrote the first draft of the manuscript. B.d.V. and A.M.J.M.v.d.M. designed and carried out molecular genetics analyses and contributed to writing the manuscript. C.M.W. analyzed whole-exome sequencing data. S.E.H. analyzed molecular data, including whole-exome sequencing data. D.E.C., S.T.B., K.M.K., P.M.C.C., S.K., B.M.R., R.G.-L., D.C., T.J.O., F.D., L.L., F.B., P.C., J.S., O.F.B., F.A., E.A., M.P., S.F.B. and I.E.S. performed clinical phenotyping. B.L.H. and X.I. performed molecular studies and interpreted that data. J.C.M., A.E.G., M.A.C. and J.G. assisted with whole-exome sequencing analysis. P.Q.T. and J.N.H. performed and interpreted quantitative gene expression analyses. M.P., S.D. and S.C. performed molecular genetics analyses and designed and performed cell biology and immunohistochemistry analyses. I.E.S. and S.F.B. designed the study, oversaw the collection and clinical characterization of families and jointly wrote the manuscript. All authors contributed to the editing of the manuscript.

Competing interests

I.E.S., S.F.B., L.M.D. and S.E.H. have submitted a patent application to develop a diagnostic test for DEPDC5 sequence mutations. The application was filed by ITEK Ventures Pty. Ltd. on behalf of the University of South Australia and by The University of Melbourne.

Corresponding authors

Correspondence to Leanne M Dibbens or Ingrid E Scheffer.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Tables 1 and 2 and Supplementary Figures 1–3

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ng.2599

Further reading